Dr Reddy’s shares fell after Goldman Sachs and Citigroup turned cautious, citing limited growth visibility, pipeline concerns and valuation risks. Brokerages flagged lower earnings potential amid generics pricing pressure and muted opportunities in semaglutide. Despite earlier optimism, analysts see downside risks persisting in the near term.